Artery Stenosis Drug Market Report 2026

The artery stenosis drug market size has grown strongly in recent years. It will grow from $2.6 billion in 2025 to $2.75 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to cardiovascular disease prevalence, aging population growth, statin therapy adoption, hypertension incidence, hospital cardiology expansion.

The artery stenosis drug market size is expected to see strong growth in the next few years. It will grow to $3.46 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to preventive cardiology focus, early diagnosis programs, combination therapy uptake, chronic disease management, outpatient cardiovascular care. Major trends in the forecast period include rising use of combination cardiovascular therapy, increased adoption of preventive drug regimens, growth in long-term statin therapy, expansion of geriatric vascular care, emphasis on stroke and heart attack prevention.

The increasing prevalence of diabetes and obesity is anticipated to drive the growth of the artery stenosis drug market in the coming years. Diabetes is a chronic condition in which the body either produces inadequate insulin or cannot effectively use it, leading to elevated blood glucose levels, while obesity is characterized by excessive body fat that increases the risk of various health complications. The rising incidence of diabetes and obesity is largely attributed to insufficient physical activity linked to increasingly sedentary work settings and screen-oriented leisure activities, which contribute to weight gain and insulin resistance. Artery stenosis drugs are required in the management of diabetes and obesity, as both conditions contribute to plaque accumulation in arteries, thereby raising the risk of heart attacks and strokes. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, diabetes accounted for 2 million deaths worldwide. Therefore, the growing prevalence of diabetes and obesity is contributing to the expansion of the artery stenosis drug market.

Major companies operating in the artery stenosis drug market are concentrating on advancing therapeutic solutions, such as sirolimus drug-coated balloons, to meet unmet medical needs in the treatment of peripheral artery disease. Sirolimus drug-coated balloons are medical devices that integrate balloon angioplasty with targeted drug delivery, releasing sirolimus, an antiproliferative agent, directly into the arterial wall during balloon inflation to suppress restenosis and enhance long-term vessel patency. For instance, in November 2024, Cordis Corporation, a US-based cardiovascular medical device company, reported positive 24-month outcomes from the Selution SFA Japan trial, highlighting the effectiveness of its Selution SLR sirolimus drug-coated balloon in treating superficial femoral artery disease. The findings demonstrated a primary patency rate of 86.8% at 24 months along with a low target lesion revascularization rate of 6.6%, reflecting sustained vessel openness and a reduced need for repeat procedures. The Selution SLR balloon provides a controlled and prolonged release of sirolimus to the arterial wall, inhibiting excessive tissue proliferation that causes re-narrowing while maintaining a strong safety profile in patients with peripheral artery stenosis.

In January 2023, AstraZeneca plc, a UK-based pharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. Through this acquisition, AstraZeneca seeks to enhance its position in the cardiorenal pipeline by incorporating CinCor’s drug candidate, baxdrostat, an aldosterone synthase inhibitor (ASI) developed for blood pressure reduction in treatment-resistant hypertension. This acquisition supports AstraZeneca’s objective of delivering innovative therapies that address complex diseases with a strong emphasis on improving patient outcomes. CinCor Pharma Inc. is a US-based biopharmaceutical company focused on developing novel therapies for cardiorenal diseases.

Major companies operating in the artery stenosis drug market are Pfizer Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Sanofi S.A., Merck & Co. Inc., Johnson & Johnson Services Inc., GSK plc, Boehringer Ingelheim, Daiichi Sankyo Company Limited, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited.

North America was the largest region in the artery stenosis drug market in 2025. The regions covered in the artery stenosis drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artery stenosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the artery stenosis drug market by increasing the cost of imported APIs, cardiovascular intermediates, and formulation excipients. These impacts have been most pronounced in statin and anticoagulant drug segments, particularly in north america and europe where API sourcing is globally diversified. Asia-pacific manufacturers have faced pricing pressures. However, tariffs have encouraged domestic production of generic cardiovascular drugs.

The artery stenosis drug market research report is one of a series of new reports that provides artery stenosis drug market statistics, including artery stenosis drug industry global market size, regional shares, competitors with a artery stenosis drug market share, detailed artery stenosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the artery stenosis drug industry. This artery stenosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artery stenosis drugs are medications prescribed to manage and treat the narrowing of arteries, known as stenosis, which can restrict blood flow and lead to related health complications. These drugs are intended to relieve symptoms, slow disease progression, and lower the risk of serious events such as heart attacks or strokes.

The primary categories of artery stenosis drugs include antiplatelet agents, anticoagulants, statins, and beta-blockers. Antiplatelet agents are medications that inhibit platelets from aggregating and forming blood clots. Based on their mechanism of action, these drugs include platelet aggregation inhibitors, thrombin inhibitors, HMG-CoA reductase inhibitors, and beta-adrenergic antagonists. Routes of administration include oral, injectable, and transdermal, while the patient groups comprise adult, geriatric, and pediatric populations.

The artery stenosis drug market consists of sales of cholesterol-lowering drugs, calcium channel blockers, and hypertension medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.